计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E174249-5mg |
5mg |
现货 ![]() |
| |
| E174249-25mg |
25mg |
现货 ![]() |
| |
| E174249-100mg |
100mg |
现货 ![]() |
| |
| E174249-250mg |
250mg |
现货 ![]() |
|
| 英文别名 | Eleclazine | 1443211-72-0 | GS-6615 | Eleclazine [INN] | 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one | PUY08529FK | 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one | 1,4-B |
|---|---|
| 规格或纯度 | Moligand™, ≥97% |
| 英文名称 | Eleclazine |
| 储存温度 | 2-8°C储存 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | Na 抑制剂 v1.5 |
| 产品介绍 |
Product Application: ELECLAZINE is a late sodium current inhibitor and a phase II agent with demonstrated pre-clinical anti-ischemic and antiarrhythmic properties. |
| 纯度 | ≥97% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504772003 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one |
| INCHI | 1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2 |
| InChi Key | YNUAEEJQYHYLMS-UHFFFAOYSA-N |
| Smiles | C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4 |
| Isomeric SMILES | C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4 |
| 分子量 | 415.372 |
| Reaxy-Rn | 23999089 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23999089&ln= |
| 溶解性 | DMSO (Slightly), Methanol (Slightly) |
|---|---|
| 熔点 | 72 - 74°C |
| 分子量 | 415.400 g/mol |
| XLogP3 | 3.700 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 415.114 Da |
| 单同位素质量Monoisotopic Mass | 415.114 Da |
| 拓扑极表面积Topological Polar Surface Area | 64.599 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 578.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 信号词 | 警告 |
|---|---|
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR et al.. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.. J Med Chem, 48 (4): (909-12). [PMID:15715460] |
| 2. Raboisson P, Marugán JJ, Schubert C, Koblish HK, Lu T, Zhao S, Player MR, Maroney AC, Reed RL, Huebert ND et al.. (2005) Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.. Bioorg Med Chem Lett, 15 (7): (1857-61). [PMID:15780621] |
| 3. Antuch W, Menon S, Chen QZ, Lu Y, Sakamuri S, Beck B, Schauer-Vukasinović V, Agarwal S, Hess S, Dömling A. (2006) Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.. Bioorg Med Chem Lett, 16 (6): (1740-3). [PMID:16427279] |
| 4. Cummings MD, Schubert C, Parks DJ, Calvo RR, LaFrance LV, Lattanze J, Milkiewicz KL, Lu T. (2006) Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.. Chem Biol Drug Des, 67 (3): (201-5). [PMID:16611213] |